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Available online 19 September 2010It is well established that full activation of T cells requires the interaction of the TCR complex with
the peptide–MHC complex (Signal 1) and additional signals (Signal 2). These second signals are
generated by the interaction of costimulatory ligands expressed on antigen presenting cells with
activating receptors on T cells. In addition, T cell responses are negatively regulated by inhibitory
costimulatory pathways. Since professional antigen presenting cells (APC) harbour a plethora of
stimulating and inhibitory surface molecules, the contribution of individual costimulatory
molecules is difficult to assess on these cells. We have developed a system of stimulator cells that
can give signal 1 to human T cells via a membrane bound anti-CD3 antibody fragment. By
expressing human costimulatory ligands on these cells, their role in T cell activation processes can
readily be analyzed.Wedemonstrate that T cell stimulator cells are excellent tools to study various
aspects of human T cell costimulation, including the effects of immunomodulatory drugs or how
costimulatory signals contribute to the in vitro expansion of T cells. T cell stimulator cells are
especially suited for the functional evaluation of ligands that are implicated in costimulatory
processes. In this study we have evaluated the role of the CD2 familymember CD150 (SLAM) and
the TNF familymember TL1A (TNFSF15) in the activation of human T cells.Whereas our results do
not point to a significant role of CD150 in T cell activation we found TL1A to potently costimulate
human T cells. Taken together our results demonstrate that T cell stimulator cells are excellent
tools to study various aspects of costimulatory processes.
© 2010 Elsevier B.V.Open access under CC BY-NC-ND license. Keywords:
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CD1501. Introduction
The two signal hypothesis of lymphocyte activation pro-
poses that T cells that receive Signal 1 via their T cell receptor
(TCR) complex depend on concomitant triggering of costimu-
latory receptors to achieve full activation (Greenwald et al.,
2005; Watts, 2005). T cell activation is also modulated by
inhibitory costimulatory receptors that are able to attenuate
TCR-signals. By acting as potent regulators of host-protective aster for Pathophysiolo-
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.at (P. Steinberger).
Y-NC-ND license. well as pathological processes, T cell costimulatory pathways
play a pivotal role in immunity (Saunders et al., 2005; Keir et al.,
2008; Nurieva et al., 2009). Consequently, such pathways are
prime therapeutic targets in diseases that are associated with
aberrant T cell responses (Ford andLarsen, 2009; Li et al., 2009).
Likewise, tumor patients or individuals suffering from chronic
viral infection might benefit from therapies that enhance
costimulatory pathways or block inhibitory receptors (Blank
and Mackensen, 2007). In this context it is evident that a more
complete understanding regarding the function of human T cell
costimulatory molecules is a prerequisite for the development
of efficient therapeutic strategies.
Studies on costimulatory pathways on human cells are
hampered by several circumstances. Antigen presenting cells
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with overlapping and redundant functions, which complicate
the assessment of the contribution of single molecules to T cell
activation processes. Studies on individual costimulatory path-
ways often rely on the use of immobilized antibodies. Such
antibodiesmight differ from the natural ligands regarding their
binding site and affinity. Furthermore, the crosslinking of
receptors by immobilized antibodies generates signals that
might not accurately reflect the effects of interaction of
costimulatory ligands with their receptors. However, there
are numerous molecules that have been categorized as
costimulatory based solely on their ability to generate a second
signal when ligated with antibodies (Leitner et al., 2010).
Recombinant proteins representing the extracellular domains
of costimulatory ligands are valuable and widely used tools to
study T cell activation processes. However, their generation is
time consuming and costly and they might differ from their
membrane resident natural counterparts regarding their
capability to modulate T cell responses.
We have developed a simple cellular system to assess the
role of costimulatory ligands in the activation of human T
cells. This system, which we have designated T cell stimulator
cells, is based on the murine thymoma cell line Bw5417 that
expresses membrane-bound anti-human CD3 single chain
antibody fragments at high or low densities. Upon retroviral
expression of human costimulatory ligands on these cells
their contribution to the activation of human T cells can
readily be determined. In this study we describe this system
in detail and demonstrate that T cell stimulator cells are an
efficient and versatile tool to study various aspects of human
T cell costimulatory processes.
2. Material and methods
2.1. Antibodies, cell culture and FACS staining
293T cells and the mouse thymoma cell line Bw5147 (short
designation within this work Bw) were cultured as described
(Pfistershammer et al., 2006, 2008). The ethical reviewboard of
the General Hospital and the Medical University of Vienna
approved the human studies performed within this work and
informed consent was obtained from the donors. PBMC were
isolated from heparinised whole blood of healthy volunteer
donors by standard density centrifugation with Ficoll-Paque
(Amersham Bioscience, Roosendaal, Netherlands). Human T
cells were obtained through depletion of CD11b, CD14, CD16,
CD19, CD33 and MHC-class II bearing cells with the respective
mAbs by MACS (Miltenyi Biotech, Bergisch Gladbach,
Germany). The mAbs to CD11b (VIM12), CD14 (VIM13),
CD33 (4D3), MHC-class II (1/47), CD80 (7-480), CD58 (1-
456) and the non-binding control antibody VIAP (calf intestine
alkaline phosphatase specific) were produced at our institute.
ThemAbs to CD14 (MEM-18)was purchased fromAn der Grub
(Kaumberg, Austria), CD19 mAb (BU12) from Ancell (Bayport,
MN), and 41BB-L and CD150/SLAM (A12) from Biolegend (San
Diego, CA). Goat anti-human TL1A/TNFSF15 antibodies were
obtained from R&D (Minneapolis, MN). FACS analysis was
performed as described previously (Pfistershammer et al.,
2006). Briefly, binding of primary antibodieswas detectedwith
PE-conjugated goat anti-mouse IgG-Fcγ specific Abs or donkey
anti-goat IgG (H+L) (both Jackson ImmunoResearch, WestGrove, PA). Expression of membrane-bound anti-CD3 antibody
fragment was detected via APC-conjugated goat anti-mouse
IgG (H+L) Abs, which reacts with the variable regions of
murine antibodies (Jackson ImmunoResearch). Fluorescence
intensity is shown on a standard logarithmic scale.
2.2. Double immunoflourescence of T cell and stimulator
cell co-cultures
Human T cells were CFSE-labeled as described in detail
(Kober et al., 2008). Irradiated T cell stimulator cells (2×106/ml)
were incubated with 0.5 μM working solution of CellTracker™
Orange CMTMR (5-and 6 (4-chloromethyl-benzoyl-amino-
tetramethylrhodamine) mixed isomers for 30 min at 37 °C in a
CO2 incubator. The reaction was stopped by washing once with
pre-warmed medium. For double-immunoflourescence
CMTMR-labeled stimulator cells (8×104/well) andCFSE-labeled
T cells (4×105/well) were co-cultured in a 24-well cell culture
plate in phenolred-free cell culture medium for 24 h or 48 h. To
visualize the stimulator cell–T cell interaction at a higher
magnification, cells were co-cultured for 24 h, fixed in 4%
paraformaldehydeandwashedoncewithmedium. Subsequent-
ly, cells were analyzed by laser scanning microscopy (LSM 410,
ZEISS) (Kriehuber et al., 2001). CellTrace™ CFSE and Cell-
Tracker™Orange CMTMRwere both purchased fromMolecular
Probes (Eugene, OR).
2.3. Generation of expression constructs encoding membrane-
bound anti-CD3 single chain fragments
cDNA derived from hybridoma cells producing the anti-
human CD3 antibody OKT3 (ATCC, Manassas, VA) was
subjected to PCR amplification using primer pairs specific
for the variable regions of the heavy chain (VH-for 5′
GGAATTCGCTAGCCCAGGTCCAGCTGCAGCAGTCT 3′, VH-rev
5′ GGGGGATCCGGTGACCGTGGTGCCTTGGCCCCAGTA 3′) and
light chain (VL-for 5 GGAATTCGAGCTCCCAAATTGTTCTCA-
CCCAGTCTCCA 3′ and VL-rev 5 GGGATCCCCACCGCCCCGG-
TTTATTTCCAACTTTGT 3′). The resulting PCR products were
digested with Nhe I plus BstE II (VH) and Sac I plus BamH I
(VL) and joined via a Sac I to BstE II fragment encoding a
(G4S)3-linker by ligation. Two distinct DNA-fragments were
generated by employing additional PCR and ligation steps:
CD5L-OKT3scFv-CD28 encoded the OKT3-single chain anti-
body fragment flanked by the CD5 leader sequence and a
BamH I to Not I fragment encoding the transmembrane and
intracellular domains of human CD28, which was amplified
using the primer pair (5′ CGCGGGGGATCCCCCAAGTCCCC-
TATTTCCCGG 3′ and 5′ GCGCCCGCGGCCGCTTTAGGAGCGA-
TAGGCTGCGAAGT 3′), whereas CD5L-OKT3-CD14 encoded
the OKT3-single chain antibody fragment flanked by the CD5
leader peptide and the leaderless human CD14 molecule
generated by fusing a CD14 BamH I to Nhe I fragment, which
was amplified using the primer pair (5′ CGCGGGGGATCCC-
ACCACGCCAGAACCTTGTGA 3′ and 5′ CCTTGAGGCGGGAG-
TACGCT 3′) to the Nhe I to Not I fragment of CD14 cDNA. Both
constructs were cloned into the retroviral expression vector
pMMP and the integrity of the synthetic expression con-
structs was confirmed by DNA-sequence analysis.
The nucleotide sequences encoding the surface expressed
anti-CD3 antibody fragments have been submitted to
133J. Leitner et al. / Journal of Immunological Methods 362 (2010) 131–141GenBank: accession ns. HM208751 – CD5L-OKT3-scFv-CD28
(protein_id ADN42858); and HM208750 – CD5L-OKT3-scFv-
CD14 (protein_id ADN42857).
2.4. Generation of T cell stimulators
Bw5147 cells were retrovirally transduced to express the
CD5L-OKT3-scFv-CD28 or the CD5L-OKT3-scFv-CD14 con-
structs. Transduction with the OKT3::CD28 yielded Bw5147
cells expressing anti-CD3 antibodies at low density; the Bw-
anti-CD3low stimulator cells. Transductionwith theOKT3::CD14
construct resulted in Bw5147 cells expressing high levels of
membrane-bound anti-CD3 antibody fragment on their surface
and were thus termed Bw-anti-CD3high stimulator cells. Single
cell clones were obtained from both Bw lines and cell clones
expressing homogenous amounts of membrane-bound anti-
CD3 antibodies were selected for further use. cDNAs encoding
human CD80, CD58, CD54, CD150, TL1A, 41BB-L and ICOS-L
were PCR amplified from a human dendritic cell library and
cloned into the retroviral expression vector pCJK2 generated in
our laboratory. Integrity of these expression plasmids was
confirmed by DNA sequencing. Using retroviral transduction
thesemolecules were expressed on the T cell stimulator cells as
described (Steinberger et al., 2004). Control stimulator cell lines
expressing no human molecule were generated by treating T
cell stimulator cells with supernatants derived from retroviral
producer cell lines transfected with empty vector DNA or a
vector encoding GFP.
2.5. T cell proliferation assays
All T cell proliferation assays were done in triplicates, means
and SD are shown. For T cell proliferation assays human T cells
(1×105/well) were co-cultured with irradiated (6000 rad) T
cell stimulator cells (2×104/well) for 72 h. In someexperiments
Adalimumab (Humira, Abbott Laboratories, Chicago, IL) or
BeriglobinP as control (CSLBehringGmbH,Marburg, Germany),
was added at a final concentration of 10 μg/ml at the onset of
culture. To assess T cell proliferation methyl-3[H]-thymidine
(final concentration: 0.025 mCi; Perkin Elmer/New England
Nuclear Corporation,Wellesley,MA)was added for the last 18 h
prior harvesting of the cells. Methyl-3[H]-thymidine uptakewas
measured as described (Pfistershammer et al., 2004).
2.6. In vitro expansion of human T cells
Purified human T cells (5×105/well) were co-cultured in
1 ml medium with 1.2×105 irradiated anti-CD3high T cell
stimulator cells expressing human costimulatory molecules
as indicated. Following 7 days of culture, T cells were
harvested, counted and analyzed for CD8+ expression. 5×105
T cells were re-cultured with 1.2×105 irradiated stimulator
cells as described above. Five rounds of stimulation were
performed. For each round of stimulation the T cell expansion
factor was calculated by dividing the starting cell number by
the cell number obtained after 7 days of stimulation.
2.7. Cellular cytotoxicity assay
Cytotoxic activity of expanded T cells was measured using
a europium release assay kit (Delfia, Perkin Elmer) followingthe manufacturer's protocol. Briefly, expanded T cells
(1×105/well) were incubated with the labeled target cells
(5×103/well; Bw-anti-CD3high cells or Bw cells not expres-
sing anti-CD3 as control) for 2 h at 37 °C. For detection of cell
lysis-associated europium release 20 μl of supernatant was
transferred to a 96-well flat bottom plate and 200 μl
enhancement solution was added. Fluorescence was mea-
sured using a time-resolved fluorometer (Victor; Perkin
Elmer). The percentage of specific cytotoxicity was calculated
as described using the formula: (experimental release-
spontaneous release)/(maximum release-spontaneous re-
lease)×100 (Pfistershammer et al., 2009).
2.8. Cytokine measurement
For cytokine measurement supernatants of T cell prolif-
eration assays were collected after 48 h and pooled from
triplicate wells. IFN-γ, IL-10 and IL-13 were measured in the
supernatants using the Luminex System 100 (Luminex, Texas,
USA).
2.9. Statistics
Two-tailed Student t test was used to assess significance.
IMB® SPSS statistics software was used for Box plot and for
analysis of variance (ANOVA) in Fig. 2.
3. Results
3.1. Generation of T cell stimulator cells
mAbs that trigger the T cell receptor complex by
interacting with CD3 molecules are widely used to study
the activation of T cells. We aimed to establish a cellular
system that can give “Signal 1” to human T cells. In a first step
we generated synthetic retroviral expression constructs that
encode a CD5 leader peptide and a single chain antibody
fragment of the anti-human CD3 antibody OKT3 fused to DNA
sequences encoding the transmembrane and intracellular
domains of human CD28 (CD5L-OKT3-scFv-CD28) or the
leaderless human CD14 (CD5L-OKT3-scFv-CD14) molecule
(Fig. 1A). These constructs were expressed on the murine
thymoma line Bw5147. Their expression was assessed by
flow cytometry using an anti-mouse IgG antibody that reacts
with the variable regions of the anti-CD3 antibody. Whereas
Bw cells expressing the CD5L-OKT3-scFv-CD14 construct
displayed high levels of membrane-bound OKT3 antibody
fragment on their surface (Bw-aCD3high), the CD5L-OKT3-
scFv-CD28 molecule was expressed at a much lower density
(Bw-aCD3low; Fig. 1A). Single cell clones that expressed
homogeneous levels of membrane-bound anti-CD3 were
established from both cell lines. Subsequently, both T cell
stimulator cell lines were transduced to express human CD80
(Bw-aCD3high-CD80; Bw-aCD3low-CD80) or treated to ex-
press empty retroviral vector (Bw-aCD3high-control, Bw-
aCD3low-control; Fig. 1B). In order to assess the T cell
stimulatory capacity of these cell lines they were irradiated
and co-cultured with purified human T cells. We found that T
cell stimulator cells expressing low amounts of membrane-
bound anti-CD3 antibody (mb-aCD3) and no human costi-
mulatory molecules did not induce significant proliferation of
Fig. 1. Generation and characterisation of T cell stimulator cells. A) Schemes of expression constructs encoding membrane-bound anti-CD3 (mb-aCD3) single chain
fragments. FACS analysis of Bw cells expressing the constructs is shown on the right. Open histograms: control cells; filled histograms: Bw cells expressingmembrane-
bound anti-CD3 single chain fragment. CD5L: CD5 leader; V
H
: variable domain of the heavy chain; V
L
: variable domain of the light chain; TM: transmembrane domain;
CT: cytoplasmic domain. B) Generation of T cell stimulator cells co-expressing anti-CD3 at high and low levels (Bw-anti-CD3high and Bw-anti-CD3low) and the
costimulatorymolecule CD80. Openhistograms: control transduced cells;filled histograms: stimulator cells expressing CD80ormock treated stimulator cells (control).
C) Human T cells were stimulated with T cell stimulator cells expressing anti-CD3high and anti-CD3low with and without CD80. 3[H]-thymidine uptake of irradiated
Bw5147 cells in the absence of T cells is also shown(far right). D)Confocalmicroscopyof CFSE-labeledT cells (green) co-culturedwithCMTMR-labeledT-cell stimulator
cells (red). Interaction of T cells and T cell stimulator cells (left). Cluster formation between T cells and stimulator cells expressing CD80 (middle) or stimulator cells
expressing no costimulatory molecule (right).
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thymidine incorporation that were measured in these co-
cultures are the result of residual uptake by the irradiated T
cell stimulator cells since similar incorporation was observed
in cultures of irradiated T cell stimulator cells where no
human T cells were present. This indicates that the murine
thymoma line Bw5147 thatwas used for the generation of our
T cell stimulator cells does not harbour accessory molecules
that can costimulate human T cells. By contrast T cell
stimulator cells that co-express low levels of anti-CD3
antibody fragments and human CD80 elicited strong prolif-
erative responses in human T cells. T cell stimulator cells
expressing membrane-bound anti-CD3 antibodies at a high
density induced moderate proliferation in human T cells even
in the absence of human costimulatory molecules and as
expected T cells activated with stimulator cells harbouring
high levels of anti-CD3 in combination with human CD80
showed the highest proliferative response (Fig. 1C). To
visualize the interaction of human T cells and stimulator
cells, we performed co-culture experiments using CFSE-
labeled T cells and CMTMR-labeled stimulator cells. Large
clusters of T cells and stimulator cells expressing CD80 can be
observed whereas much smaller clusters are formed when T
cells were activated by stimulator cells expressing anti-CD3
but no human costimulatory molecule (Fig. 1D).
3.2. Side by side comparison of different
costimulatory molecules
T cell stimulator cells transduced to express different
costimulatory molecules are excellent tools to compare these
ligands regarding their capacity to activate human T cells. We
have generated stimulator cell lines retrovirally expressing
different costimulatory molecules at high levels (Fig. 2). The
resultant cell lines were used to stimulate purified T cells
isolated from different healthy donors and T cell proliferation
was assessed. As shown in Fig. 2B stimulation of human T cellsFig. 2. Comparison of different costimulatory ligands. T cell stimulator lines
expressing high levels of anti-CD3 antibodies and the indicated costimula-
tory ligands or no costimulatory molecule (control) were co-cultured with
purified human T cells. 3[H]-thymidine uptake was assessed following 3 days
of co-culture. Box plots show the results of 8 independent experiments with
T cells from different donors. Circles indicate outliers. Stars indicate
significant difference (pb0.05, n=8) from the stimulator cell type listed
on the left.in the presence of the costimulatory molecules used in this
study (CD80, ICOSL, CD58, CD54 and 4-1BBL) significantly
enhanced T cell proliferation compared to T cells co-cultured
with stimulator cells expressing no human costimulatory
molecule. Furthermore, our data show that CD80 was the
strongest costimulatory ligand tested in these experiments
and demonstrate that among the other molecules analyzed
CD58 is the most potent inducer of T cell proliferation.
3.3. The use of T cell stimulator cells to assess the role of
immunomodulatory drugs in T cell activation
There is an increasing number of immunosuppressive and
immunomodulatory drugs for treatment of patients suffering
from autoimmune diseases and recipients of hematopoietic
stem cells or solid organs. Many of these drugs target fast
dividing cells whereas others specifically suppress T cells or
counteract inflammatory processes. Antibodies or receptor
fusion proteins that block the cytokine TNF-α are successfully
used in patients suffering from psoriasis, rheumatoid arthritis
and various other autoimmune diseases (Aringer and Smolen,
2008; Bosani et al., 2009; Taylor and Feldmann, 2009). TNF-α
is a pleiotrophic cytokine and the beneficial effects of TNF-α
blockade are mainly ascribed to its capacity to prevent and
down-modulate proinflammatory processes. Whereas other
members of the TNF-family have been shown to act as potent
costimulatory molecules, few studies have addressed the
ability of TNF-α to directly contribute to T cell activation
processes. We found that expressing TNF-α on T cell
stimulator cells enhances their ability to induce proliferation
in purified human T cells (Fig. 3A). Furthermore,we show that
Adalimumab, a humanized therapeutic antibody that targets
TNF-α, reduced proliferation of T cells activated via different
costimulatory molecules (Fig. 3B). Taken together these
results indicate that TNF-α gives a costimulatory signal to
human T cells and that TNF-α blockade reduces human T cell
responses independent of accessory cells.
3.4. The use of T cell stimulator cells to assess the role of different
costimulatory molecules in the in vitro expansion of human T cells
Adoptive T cell transfer is a promising therapeutic strategy
in the treatment of malignancies, and to combat virus
infections (Ho et al., 2002; June, 2007; Berger et al., 2009).
Such approaches often depend on the efficient in vitro
expansion of antigen specific T cells. We used T cell stimulator
cells expressing individual costimulatory molecules or com-
binations thereof to assess their capacity to expand human T
cells in vitro. In line with previous data we found that 4-1BB
signals enhance the expansion of T cells costimulated via
CD28 (Maus et al., 2002). Furthermore, our results demon-
strate that costimulation via CD2 can also potently increase
the expansion of human T cells. Stimulator cells co-expressing
CD80, CD58 and 4-1BBL induced significantly stronger T cell
expansion compared to stimulator cells not expressing CD80.
This underlines the importance of CD28 signals and suggests
that the combination of CD80, CD58 and 4-1BBL might be
especially suited for the expansion of human T cells (Fig. 4).
Importantly, we found that during 5 rounds of stimulation in
the presence of these costimulatory ligands their effector
function was retained as the expanded T cells were able to
Fig. 3. The therapeutic TNF-α blocking antibody Adalimumab down-
modulates human T cell responses. A) T cell stimulator cells expressing
anti-CD3 antibodies at high levels (control) and T cell stimulator cells
expressing anti-CD3 antibodies and human TNF-α were used to stimulate
purified human T cells in the presence of control antibodies (control Ab) or
the therapeutic anti-TNF-α antibody Adalimumab. B) T cell stimulator cells
expressing the indicated costimulatory molecules were used to stimulate
purified human T cells in the presence of control antibodies or Adalimumab
(10 μg/ml). Data shown are representative for at least 5 independently
performed experiments.
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surrogate antigen (Fig. 4D).
3.5. The use of T cell stimulator cells to assess the role of CD150
and TL1A in the activation of human T cells
There are a large number of human molecules that were
described to costimulate T cell activation (Leitner et al.,
2010). Although for several of these molecules such a role is
well established, there are still some ligands where a limited
number of studies have addressed their function in T cell
stimulation. We have selected two such molecules, TL1A and
CD150, to study their function in T cell activation using our
system of stimulator cells (Fig. 5A). For comparison T cell
stimulator cells expressing CD58, a member of the CD2
superfamily, and 4-1BBL, a member of the TNF-SF, which are
well established costimulatory ligands were also used.
TL1A (TNF-like molecule 1A), the newest member of the
TNF-superfamily, is described to costimulate murine and
human T cell proliferation via interaction with its receptor
death receptor 3 (DR3, TRAMP) (Migone et al., 2002; Pappu et
al., 2008; Zhan et al., 2009). In our experiments T cell
stimulator cells expressing high levels of anti-CD3 and TL1Astrongly enhanced the proliferation of human T cells (Fig. 5B).
This costimulatory effect was observed with CD4+ and CD8+
T cells (Fig. 5D). In linewith previous studies TL1A stimulation
resulted in the induction of IFN-γ (Biener-Ramanujan et al.,
2010). In addition, we obtained elevated levels of IL-10 and IL-
13 in supernatants of TL1A stimulated T cell cultures (Fig. 5C).
CD150 (SLAM, signaling lymphocyte activating molecule)
is a CD2 family member, expressed on activated human T
cells. All previous studies that reported a costimulatory role of
thismoleculewere based on the use of monoclonal antibodies
to trigger the CD150 molecule on T cells (Cocks et al., 1995;
Aversa et al., 1997; Howie et al., 2002). CD150 is a self-ligating
molecule and no other binding partners have been described.
Thus, we wanted to analyze whether the costimulatory effect
was also observed upon engagement of T cell-expressed
CD150 with its natural ligand. Therefore, we generated
stimulator cells expressing CD150 in conjunction with anti-
CD3. When co-culturing these stimulator cells with human T
cells, no significant contribution of this interaction to T cell
proliferation and cytokine production was observed (Fig. 5B,
C). In some of our experiments reduced proliferation rates of
human T cells were observed in the presence of human
CD150 but additional experiments are required to confirm
that CD150 can function as a negative regulator of T cell
responses.
4. Disscussion
During APC–T cell interaction a complex interplay of
numerous cell surface molecules modulates cellular immune
responses by either enhancing or inhibiting T cell receptor
complex signalling. Thus, assessing the function of individual
costimulatory ligands using natural APC is a difficult task.
With our T cell stimulator cells we have generated an
experimental tool for studying individual costimulatory
ligands in a cellular system, but detached from the context
of numerous other molecules involved in the regulation of T
cell activation that are expressed on professional APC.
Whereas similar cellular systems that have been termed
artificial APC (aAPC) use cells engineered to express Fc-γ
receptors (CD32 or CD64) and depend on the addition of anti-
CD3 antibodies (Thomas et al., 2002; Suhoski et al., 2007;
Gong et al., 2008) we used cell lines that stably express
membrane-bound anti-CD3 antibody fragments. Using dif-
ferent anti-CD3 expression constructs we have generated two
cell clones that stably express different levels of anti-CD3
antibody fragments: A construct where the anti-CD3 anti-
body fragments are linked to the transmembrane domain of
human CD28 molecules yielded Bw-aCD3low stimulator cells
that give a weak signal 1 to human T cells, whereas a
construct encoding anti-CD3 antibody fragments fused to the
human CD14 molecule was used to generate cells expressing
high levels of GPI-anchored anti-CD3 antibody fragments
(Bw-aCD3high; Fig. 1). The GPI-anchored anti-CD3 antibody
fragment is efficiently targeted to lipid rafts and has also
successfully been used for the stimulation and manipulation
of human T cells with immunosomes — virus-like particles
decorated with TCR/CD3 ligands, costimulatory molecules
and modified cytokines (Derdak et al., 2006; Kueng et al.,
2007; Leb et al., 2009; Kueng et al., 2010). Another important
difference between aAPC and stimulator cells is the cell type
Fig. 4. Costimulatory signals and the in vitro expansion of human T cells. T cells were subjected to five rounds of expansion using T cell stimulator cells expressing
high levels of the indicated molecules. A) Box plots representing the average fold expansion per round of stimulation. T cell stimulator cells co-expressing CD80,
CD58 and 4-1BBL induced significantly higher T cell expansion than the indicated T cell stimulator cells (pb0.05). The total expansion of T cells during five rounds
of stimulation (B) and the calculated CD8+ T cell number that would have been obtained from 5×105 T cells (C) is also shown. D) Effector function of T cells
expanded for 5 rounds in the presence of the indicated costimulatory molecules was analyzed by a europium release assay. T cell stimulator cells expressing high
levels of anti-CD3 (black bars) were used as target cells and Bw cells expressing no anti-CD3 served as control cells (white bars). Percentage of specific lysis is
shown.
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K562 cell line and T cell stimulator cells are derived from the
murine thymoma line Bw5147. Whereas K562 cells contain
surface molecules that enhance T cell–APC interactions
(Suhoski et al., 2007), Bw cells appear to be devoid of
molecules that promote the proliferation of human T cells
that receive a weak signal 1 (Fig. 1B). Thus, T cell stimulator
cells are especially suited to study molecules that exert weak
costimulatory effects. Furthermore, with this system it is also
possible to compare different accessory molecules regarding
their capacity to costimulate activation and proliferation of
human T cells. Experiments where we have performed a side
by side comparison of ligands belonging to different molecule
families demonstrated a potent ability of CD58 to costimulate
the activation of human T cells (Fig. 2).In addition to the numerous different immunosuppressive
drugs that are already used in the clinic to down-modulate
T cell responses there are many additional compounds or
biologics that are currently tested regarding their efficacy
and safety for human use. Especially in the case of antibodies
that often have limited or no reactivity with the non-human
orthologues of their target antigens, extensive in vitro testing
in human systems is highly warranted. Since costimulators
govern the activation of T cells, their interplay with T cell
suppressive antibodies and drugs is of great interest. Here,
we have used our system of T cell stimulator cells to analyze
the effect of Adalimumab, a therapeutic antibody to TNF-α,
on T cell activation. We show that TNF-α has a costimulatory
effect on human T cells and that TNF-α blockade reduces
the proliferation of T cells, independent of accessory cells
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of the molecules used for their activation. However, we have
observed that the capacity of some therapeutic antibodies
and immunosuppressive drugs to diminish T cell proliferation
and cytokine production is potently modulated by different
costimulatory signals (our unpublished results).
The efficient in vitro expansion of antigen specific T cells
crucially depends on appropriate costimulatory signals to
ensure the generation of large amounts of potent effector
cells. Different combinations of costimulatory ligands can be
readily expressed on stimulator cells. The resultant stimulator
cell lines can be tested in parallel to identify combinations of
stimulatory molecules that potently drive expansion of
human T cells in vitro. Our results indicate that concomitant
stimulation via their CD28, CD2 and 4-1BB receptors leads to
an efficient expansion of T cells, which retain their effector
function during several rounds of stimulations (Fig. 4). These
results, together with our findings summarized in Fig. 2,
underline the potency and importance of the CD2–CD58
pathway for the activation of human T cells. CD2 was one of
the first T cell costimulatory receptors identified (Meuer et al.,
1984) and despite its importance this pathway is currently
receiving limited attention. This is in part due to the fact that
CD58 lacks a murine orthologue and demonstrates the
current emphasis on mouse model systems to study the
costimulatory pathways.
There are an ever growing number of ligands that have
been implicated to play a role in T cell costimulatory
processes and contradictory results have been reported for
several of these molecules (Leitner et al., 2010). We believe
that T cell stimulator cells are especially suited to assess the
function of accessory molecules during T cell activation since
they allow analyzing human T cell responses under condi-
tions that only differ regarding the presence of the molecules
of interest. We have recently used stimulator cells expressing
PD-L2 and B7-H3, two members of the extended B7 family, to
address their function during the activation of human T cells
(Pfistershammer et al., 2006; Leitner et al., 2009). In these
studies we could show that these molecules consistently
inhibited T cell responses and our experiments did give any
evidence for positive costimulatory functions for human PD-
L2 and B7-H3. The CD2 superfamily member CD150 and the
TNF-SF member TL1A have both been described to costimu-
late T cell activation. CD150 is a self-ligating receptor,
whereas TL1A binds to DR3 a member of the TNFR-SF.
However, few studies on these molecules have directly
analyzed the consequences of the interaction of CD150 or
TL1A with human T cells. In the present study we have
generated T cell stimulator cell lines expressing CD150 andFig. 5. The role of CD150 and TL1A in the activation of human T cells. A) Characterisat
4-1BBL, TL1A, CD150 or control stimulator cells expressing no costimulatory mo
antibodies on stimulator cells; open histograms: control Bw cells. Lower panel: T cell
antibodies specific for these molecules (filled histograms). Open histograms: reactiv
stimulated with stimulator cells expressing high levels of anti-CD3 in conjunction w
assessed by measuring 3[H]-thymidine uptake. Presence of TL1A significantly enha
human T cells proliferation (ns, not significant). Data show +/− SD of triplicate
independently performed. C) Human T cells were stimulated with stimulator cells
CD150 or no costimulatory molecule (control). Culture supernatant was harvested a
shown is representative for the 3 independently performed. D) Purified human CD
CD3high in conjunction with TL1A, CD150 or control. Data show +/− SD of triplica
outcome.TL1A and used them to stimulate purified human T cells. Our
results demonstrate that the presence of TL1A during T cell
activation significantly costimulates their proliferation and
production of cytokines, whereas T cells stimulated in the
presence of stimulator cells expressing CD150 did not show
enhanced proliferation and cytokine production. Previous
studies that have described a positive costimulatory function
for CD150 have used antibodies to crosslink the CD150
molecules on T cells (Cocks et al., 1995; Aversa et al., 1997). In
contrast, we have used T cell stimulator cells expressing its
natural ligand CD150, to assess the role of CD150–CD150
interaction in the activation of T cells. Our results, which
suggest that CD150 does not function as a classical T cell
costimulatory molecule, underline the importance of using
natural ligands to study the functional consequences of
receptor–ligand pairs implicated in T cell activation process-
es. The homophilic interaction of CD150 is of particular low
affinity (Kd 200 mM; (Chattopadhyay et al., 2009)), which
might explain the different outcome of our experiments
compared to studies that used antibodies. It has previously
been suggested that antibody-induced SLAM/CD150 activa-
tion may not fully mimic the physiological role of CD150,
because mice deficient in this molecule exhibit essentially
normal levels of IFN-γ, whereas the ligation of T cell-
expressed CD150 by antibodies promotes strong IFN-γ
secretion (Ostrakhovitch and Li, 2006). Further studies are
required to address the physiological role of CD150 during
human T cell activation. Since T cells that express costimu-
latory ligands can receive potent costimulatory signals
(“autocostimulation”) it is also possible that homotypic
interaction of CD150 in cis plays a role during human T cell
activation (Stephan et al., 2007).
Taken together our results demonstrate that the system of
T cell stimulator cells is a useful tool to assess the function of
costimulatory ligands. In particular they are suited to
compare the function of individual costimulatory molecules
and analyze their effect on different T cell subsets and in
context of a strong or weak signal 1. Since professional APC
like DC harbour stimulatory as well as inhibitory ligands, the
interplay of positive and negative signals determines the
outcome of T cell responses. We have previously shown that
combinations of costimulatory molecules can be expressed
and analyzed on T cell stimulator cells (Kober et al., 2008).
We are currently using our system of stimulator cells to
analyze the interplay of defined costimulatory and coinhibi-
tory molecules during the activation of human T cells. Studies
on individual costimulatory pathways can complement
investigations using experimental systems employing natural
human APC or animal studies to get a better insight into theion of T cell stimulator cells expressing anti-CD3high in conjunction with CD58,
lecule by FACS. Upper panel filled histograms: expression of mb-anti-CD3
stimulator cells expressing CD58, 4-1BBL, TL1A, and CD150 were probed with
ity of the indicated antibodies with control Bw cells. B) Human T cells were
ith CD58, 4-1BBL, TL1A, CD150 or control stimulator cells. Proliferation was
nced T cell proliferation (pb0.0001, n=9), whereas CD150 had no effect on
s from one experiment. The experiment shown is representative for the 9
expressing high levels of anti-CD3 in conjunction with CD58, 4-1BBL, TL1A,
fter 72 h and subjected to multiplex cytokine measurement. The experiment
4+ and CD8+ T cells were co-cultured with stimulator cells expressing anti-
tes from one experiment. The shown experiment was repeated with similar
140 J. Leitner et al. / Journal of Immunological Methods 362 (2010) 131–141complex interplay of the numerous accessory surface mole-
cules that govern human T cell responses.
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